Geneoscopy announced today the hiring of Haytham Gareer, MD, Ph.D. as the startups Chief Medical Officer. The St. Louis based startup is developing a screening methodology to noninvasively diagnose colorectal cancer using bio-markers in stool samples.
Andrew Barnell, Geneoscopy CEO
“From my perspective the reason we hired Dr. Gareer is to be the voice of Geneoscopy to key stakeholders including patients, physicians and insurers,” Geneoscopy CEO Andrew Barnell told the 4thEst8. “He’s really helping guide the way we talk with those folks — the value proposition and ensuring we’re doing everything internally to meet the needs of those stakeholders.”
A trained surgical oncologist, Gareer brings two decades of medical and clinical affairs experience, and the company says they’ll play a key role in launching its non-invasive colorectal cancer screening test.
Haytham Gareer, Geneoscopy CMO
“Although the initial focus is on colorectal cancer detection and prevention, the company’s robust platform has the potential to address a broad range of unmet needs in managing gastrointestinal conditions,” Gareer said in a statement. “I am excited to join this talented team and drive its mission forward.”
According to CrunchBase Geneoscopy has raised a total of $7.9M since its formation in 2015, most recently a Series A round closed in Oct. 2019. Investors include NT Asset, Lightchain, Cultivation Capital, Rodger Riney, Missouri Technology Corporation, Billiken Angels Network and the Dorm Room Fund.
Links:
On the 4thEst8:
